Targeted Therapies and their Impact on Melanoma

Steven O’Day, MD
Video Categories: Targeted Therapies

Dr. Steve O’Day works with melanoma and has seen great breakthroughs in targeted therapies and their impact on the disease.
September 2, 2015

Aspirations for the Launch of Ixazomib

Ixazomib may have the potential for great combinability with other drugs, according to Dixie-Lee Esseltine, MD and George Mulligan, PhD. Combination therapy improves compliance, adherence, and quality of life among patients.

December 3, 2013

The Role of Hedgehog Pathway Inhibition in Advanced Basal Cell Carcinoma

In the first WCMC clinical commentary entitled, The Role of Hedgehog Pathway Inhibition in Advanced Basal Cell Carcinoma, Dirk Schadendorf, MD; Nicole Basset-Seguin, MD, PhD; Aleksander Sekulic, MD, PhD discuss how the hedgehog pathway plays a critical role in developing basal cell carcinoma and how inhibitors are providing new strategies [ Read More ]